GNRC landed the day's most notable upgrade. Analysts moved the $15 billion power generation company from Hold to Buy. The consensus target price sits at $290.27.
The move follows rising demand for backup power systems. Grid reliability concerns and data center buildout have kept Generac in focus for much of 2026.
Pharma saw a split session. LLY received a target price bump to $1,228, up from $1,224. The $1 trillion pharma giant carries just 1% short interest. Analysts remain overwhelmingly bullish with 22 Buy ratings.
REGN got the opposite treatment. Analysts trimmed the target to $822 from $825. The stock carries 21 Sell recommendations — the highest among major biopharma names today. That negative skew stands out for a $65 billion company.
AMGN and BIIB both saw target price increases. Amgen's consensus target moved to $354.97. Biogen's edged up to $222.38.
RMD also got a target lift. ResMed's average analyst target rose to $260.47 from $256.29. The sleep device maker holds 18 Buy ratings with zero Sells.
Across materials, SHW and PPG both received small upward target revisions from analysts covering the coatings sector.
ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
